- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01163266
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying dosages of vortioxetine.
The study enrolled 462 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):
- Vortioxetine 10 mg
- Vortioxetine 20 mg
- Placebo (dummy inactive capsule) - this was a capsule that looked like the study drug but had no active ingredient.
All participants were asked to take one capsule at the same time each day throughout the study.
This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 13 weeks. Participants made 9 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Anaheim, California, United States
-
Cerritos, California, United States
-
Costa Mesa, California, United States
-
Encino, California, United States
-
Garden Grove, California, United States
-
Irvine, California, United States
-
Pico Rivera, California, United States
-
Riverside, California, United States
-
-
Colorado
-
Colorado Springs, Colorado, United States
-
-
Connecticut
-
Norwich, Connecticut, United States
-
-
Florida
-
Maitland, Florida, United States
-
North Miami, Florida, United States
-
Orange City, Florida, United States
-
Orlando, Florida, United States
-
St. Petersburg, Florida, United States
-
-
Georgia
-
Smyrna, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
Joliet, Illinois, United States
-
Skokie, Illinois, United States
-
-
Kansas
-
Wichita, Kansas, United States
-
-
Louisiana
-
Lake Charles, Louisiana, United States
-
-
Massachusetts
-
Worcester, Massachusetts, United States
-
-
Missouri
-
St. Charles, Missouri, United States
-
St. Louis, Missouri, United States
-
-
New Jersey
-
Willingboro, New Jersey, United States
-
-
New York
-
Buffalo, New York, United States
-
New York, New York, United States
-
Rochester, New York, United States
-
-
Ohio
-
Cinti, Ohio, United States
-
Dayton, Ohio, United States
-
Middleburg Heights, Ohio, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Norristown, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
-
Texas
-
Irving, Texas, United States
-
-
Virginia
-
Richmond, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Wisconsin
-
Brown Deer, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Suffers from a major depressive episode recurrent as the primary diagnosis according to the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.
- Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits.
- Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits.
Exclusion Criteria:
- Has previously participated in a Lu AA21004 clinical study.
Has 1 or more the following:
- Any current psychiatric disorder other than Major Depressive Disorder as defined in the DSM-IV
- Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder defined in the DSM-IV-TR.
- Diagnosis of alcohol or other substance disorder (except nicotine and caffeine) as defined in the DSM-IV-TR that has not been in sustained full remission for at least years prior to screening (participant must also have negative urine drug screen prior to Baseline).
- Presence or history of a clinically significant neurological disorder (including epilepsy)
- Neurodegenerative disorder.
- Any Axis II disorder that might compromise the study.
- Has a thyroid stimulating hormone value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator.
- Has clinically significant abnormal vital signs as determined by the investigator.
- Has an abnormal Electrocardiogram.
- Has an alanine aminotransferase, aspartate aminotransferase or total bilirubin level greater than 1.5 times the upper limits of normal.
- Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication.
- Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
- Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
- Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance. For the purposes of this protocol the following conditions are considered unstable due to the potential impact on assessment of MDD response: pain disorder, chronic fatigue syndrome, fibromyalgia, and obstructive sleep apnea.
- Has a significant risk of suicide according to the investigator's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo-matching capsules, orally, once daily for up to 8 weeks.
|
Vortioxetine placebo-matching capsules
|
Experimental: Vortioxetine 10 mg
Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
|
Encapsulated vortioxetine immediate release tablets
Other Names:
|
Experimental: Vortioxetine 20 mg
Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
|
Encapsulated vortioxetine immediate release tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
Time Frame: Baseline and Week 8
|
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal).
The 10 items represent the core symptoms of depressive illness.
The overall score ranges from 0 (symptoms absent) to 60 (severe depression).
A decrease in the total score or on individual items indicates improvement.
Least squares (LS) means are from a mixed model for repeated measurements (MMRM) analysis of covariance (ANCOVA) with treatment, center, week, treatment-by-week interaction, Baseline MADRS total score-by-week as fixed effects.
|
Baseline and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants in MADRS Remission at Week 8
Time Frame: Week 8
|
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10.
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6.
The 10 items represent the core symptoms of depressive illness.
The overall score ranges from 0 (symptoms absent) to 60 (severe depression).
Decrease in the total score or on individual items indicates improvement.
|
Week 8
|
Percentage of Participants With a MADRS Response at Week 8
Time Frame: Baseline and Week 8
|
Response is defined as a participant with a ≥50% decrease in Montgomery Åsberg Depression Rating Scale (MADRS) total score from Baseline.
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6.
The 10 items represent the core symptoms of depressive illness.
The overall score ranges from 0 (symptoms absent) to 60 (severe depression).
Decrease in the total score or on individual items indicates improvement.
|
Baseline and Week 8
|
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
Time Frame: Baseline and Week 8
|
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities.
The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely).
The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
LS means were from mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline SDS total score-by-week as fixed effects.
|
Baseline and Week 8
|
Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 8
Time Frame: Week 8
|
The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
LS means were from a mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline Clinical Global Impression Scale-Severity of Illness Scale (CGI-S) score-by-week as fixed effects.
|
Week 8
|
Change From Baseline in MADRS Total Score at Week 8 in Participants With Baseline Hamilton Anxiety Scale (HAM-A) Total Score ≥20
Time Frame: Baseline and Week 8
|
The MADRS is a depression rating scale consisting of 10 items, each rated 0 (normal) to 6 (most abnormal). The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from a mixed model for repeated measurements (MMRM) ANCOVA with treatment, center, week, treatment-by-week interaction, Baseline MADRS total score-by-week as fixed effects. The HAM-A is a 14 item rating scale to quantify anxiety severity rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56, where lower scores indicate mild severity. |
Baseline and Week 8
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord. 2020 Feb 15;263:258-266. doi: 10.1016/j.jad.2019.11.074. Epub 2019 Nov 13.
- Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015 May;76(5):575-82. doi: 10.4088/JCP.14m09335.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Depression
- Depressive Disorder
- Disease
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Vortioxetine
Other Study ID Numbers
- LuAA21004_316
- U1111-1115-8770 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States